MA42301A - Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone - Google Patents

Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone

Info

Publication number: MA42301A
Authority: MA; Morocco
Prior art keywords: iodophenylamino; azetidin; methanone; piperidin; difluoro
Prior art date: 2015-06-30

Application number

MA042301A

Other languages

English (en)

Inventor

Adrian St Clair Brown

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-30

Filing date

2016-06-30

Publication date

2018-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56411938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-30 Application filed by Exelixis Inc filed Critical Exelixis Inc

2018-05-09 Publication of MA42301A publication Critical patent/MA42301A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

MA042301A 2015-06-30 2016-06-30 Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone MA42301A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562187009P	2015-06-30	2015-06-30

Publications (1)

Publication Number	Publication Date
MA42301A true MA42301A (fr)	2018-05-09

Family

ID=56411938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042301A MA42301A (fr)	2015-06-30	2016-06-30	Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone

Country Status (26)

Country	Link
US (3)	US10590102B2 (fr)
EP (1)	EP3317264B1 (fr)
JP (3)	JP7338950B2 (fr)
KR (1)	KR102695324B1 (fr)
CN (2)	CN107810183A (fr)
AR (1)	AR105483A1 (fr)
AU (2)	AU2016288209B2 (fr)
CA (1)	CA2990222C (fr)
CL (1)	CL2017003475A1 (fr)
CO (1)	CO2018000086A2 (fr)
CR (1)	CR20180056A (fr)
DK (1)	DK3317264T3 (fr)
FI (1)	FI3317264T3 (fr)
HK (1)	HK1252433A1 (fr)
IL (2)	IL256423B (fr)
MA (1)	MA42301A (fr)
MX (1)	MX390250B (fr)
MY (1)	MY192545A (fr)
PE (1)	PE20180692A1 (fr)
PH (1)	PH12017502414A1 (fr)
RU (2)	RU2021132394A (fr)
SG (1)	SG10202105196YA (fr)
TW (2)	TWI775187B (fr)
UA (1)	UA124728C2 (fr)
WO (1)	WO2017004393A1 (fr)
ZA (1)	ZA201708760B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20180670T1 (hr)	2012-10-12	2018-07-13	Exelixis Inc.	Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
PL3316867T3 (pl) *	2015-06-30	2021-10-11	Genentech, Inc.	Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
AR105483A1 (es)	2015-06-30	2017-10-11	Exelixis Inc	Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
WO2018134254A1 (fr)	2017-01-17	2018-07-26	Heparegenix Gmbh	Inhibiteurs de protéine kinase pour favoriser la régénération du foie, ou pour réduire ou prévenir la mort des hépatocytes
GB201717809D0 (en) *	2017-10-30	2017-12-13	Azad Pharmaceutical Ingredients Ag	Process for the production of cobimetinib
WO2020187674A1 (fr)	2019-03-15	2020-09-24	Sandoz Ag	Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
AU2023384196A1 (en) *	2022-11-25	2025-06-12	Msn Laboratories Private Limited, R&D Center	Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR051248A1 (es)	2004-10-20	2007-01-03	Applied Research Systems	Derivados de 3-arilamino piridina
EP1904480A2 (fr)	2005-05-23	2008-04-02	Novartis Pharma AG	Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
EP1934174B1 (fr) *	2005-10-07	2011-04-06	Exelixis, Inc.	Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
ATE539752T1 (de)	2006-08-16	2012-01-15	Exelixis Inc	Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
JP5311673B2 (ja)	2006-12-14	2013-10-09	エグゼリクシス，インコーポレイテッド	Ｍｅｋ阻害剤の使用方法
WO2008124085A2 (fr)	2007-04-03	2008-10-16	Exelixis, Inc.	Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
HRP20180670T1 (hr)	2012-10-12	2018-07-13	Exelixis Inc.	Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
CA2904338C (fr)	2013-03-05	2022-07-05	University Of Tennessee Research Foundation	Utilisation de derives de l'imidazole conjointement a un inhibiteur brafou a un inhibiteur mek dans le traitement du cancer
KR20150127203A (ko)	2013-03-14	2015-11-16	제넨테크, 인크.	Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
AR105483A1 (es)	2015-06-30	2017-10-11	Exelixis Inc	Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

2016
- 2016-06-24 AR ARP160101900A patent/AR105483A1/es unknown
- 2016-06-30 WO PCT/US2016/040444 patent/WO2017004393A1/fr not_active Ceased
- 2016-06-30 AU AU2016288209A patent/AU2016288209B2/en active Active
- 2016-06-30 CN CN201680039354.4A patent/CN107810183A/zh active Pending
- 2016-06-30 EP EP16738971.7A patent/EP3317264B1/fr active Active
- 2016-06-30 JP JP2017568050A patent/JP7338950B2/ja active Active
- 2016-06-30 IL IL256423A patent/IL256423B/en unknown
- 2016-06-30 FI FIEP16738971.7T patent/FI3317264T3/fi active
- 2016-06-30 PE PE2017002869A patent/PE20180692A1/es unknown
- 2016-06-30 MY MYPI2017001962A patent/MY192545A/en unknown
- 2016-06-30 HK HK18111734.8A patent/HK1252433A1/zh unknown
- 2016-06-30 DK DK16738971.7T patent/DK3317264T3/da active
- 2016-06-30 CA CA2990222A patent/CA2990222C/fr active Active
- 2016-06-30 TW TW109136325A patent/TWI775187B/zh active
- 2016-06-30 KR KR1020187000067A patent/KR102695324B1/ko active Active
- 2016-06-30 CN CN202410400619.5A patent/CN118290395A/zh active Pending
- 2016-06-30 UA UAA201800769A patent/UA124728C2/uk unknown
- 2016-06-30 RU RU2021132394A patent/RU2021132394A/ru unknown
- 2016-06-30 IL IL295052A patent/IL295052A/en unknown
- 2016-06-30 MA MA042301A patent/MA42301A/fr unknown
- 2016-06-30 TW TW105120825A patent/TWI710556B/zh active
- 2016-06-30 SG SG10202105196YA patent/SG10202105196YA/en unknown
- 2016-06-30 MX MX2017017037A patent/MX390250B/es unknown
- 2016-06-30 RU RU2018103172A patent/RU2762181C2/ru active
- 2016-06-30 CR CR20180056A patent/CR20180056A/es unknown
2017
- 2017-12-21 ZA ZA2017/08760A patent/ZA201708760B/en unknown
- 2017-12-22 US US15/852,280 patent/US10590102B2/en active Active
- 2017-12-22 PH PH12017502414A patent/PH12017502414A1/en unknown
- 2017-12-29 CL CL2017003475A patent/CL2017003475A1/es unknown
2018
- 2018-01-05 CO CONC2018/0000086A patent/CO2018000086A2/es unknown
2020
- 2020-01-17 US US16/746,161 patent/US11254649B2/en active Active
- 2020-11-05 JP JP2020184868A patent/JP2021035967A/ja not_active Withdrawn
2021
- 2021-01-14 AU AU2021200202A patent/AU2021200202B2/en active Active
- 2021-11-08 US US17/521,396 patent/US20220056010A1/en not_active Abandoned
2022
- 2022-11-07 JP JP2022178184A patent/JP2023025000A/ja active Pending

Also Published As

Publication number	Publication date
US20180346442A1 (en)	2018-12-06
AU2016288209A1 (en)	2018-02-08
IL256423B (en)	2022-09-01
AR105483A1 (es)	2017-10-11
IL295052A (en)	2022-09-01
WO2017004393A1 (fr)	2017-01-05
RU2018103172A3 (fr)	2019-10-31
JP2018519318A (ja)	2018-07-19
TW202108568A (zh)	2021-03-01
CN118290395A (zh)	2024-07-05
BR112017028516A2 (pt)	2018-08-28
MY192545A (en)	2022-08-26
NZ739160A (en)	2024-10-25
RU2021132394A (ru)	2021-11-18
PE20180692A1 (es)	2018-04-23
RU2018103172A (ru)	2019-07-31
CA2990222A1 (fr)	2017-01-05
IL256423A (en)	2018-02-28
EP3317264A1 (fr)	2018-05-09
HK1252433A1 (zh)	2019-05-24
AU2021200202B2 (en)	2022-09-08
KR102695324B1 (ko)	2024-08-13
AU2016288209B2 (en)	2020-10-22
UA124728C2 (uk)	2021-11-10
EP3317264B1 (fr)	2025-09-10
TW201718535A (zh)	2017-06-01
DK3317264T3 (da)	2025-12-01
JP7338950B2 (ja)	2023-09-05
CL2017003475A1 (es)	2018-07-13
US20200255398A1 (en)	2020-08-13
NZ777527A (en)	2024-10-25
MX390250B (es)	2025-03-20
CO2018000086A2 (es)	2018-04-10
SG10202105196YA (en)	2021-06-29
US20220056010A1 (en)	2022-02-24
TWI710556B (zh)	2020-11-21
US11254649B2 (en)	2022-02-22
JP2021035967A (ja)	2021-03-04
JP2023025000A (ja)	2023-02-21
CA2990222C (fr)	2023-09-26
AU2021200202A1 (en)	2021-03-18
US10590102B2 (en)	2020-03-17
PH12017502414A1 (en)	2018-06-25
CN107810183A (zh)	2018-03-16
CR20180056A (es)	2018-05-25
MX2017017037A (es)	2018-04-30
ZA201708760B (en)	2022-06-29
TWI775187B (zh)	2022-08-21
KR20180021775A (ko)	2018-03-05
RU2762181C2 (ru)	2021-12-16
FI3317264T3 (fi)	2025-12-05

Publication	Publication Date	Title
IL283979B (en)	2022-04-01	3,1-thiazol-2-yl converted benzamides
MA42301A (fr)	2018-05-09	Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
DK3355884T3 (da)	2021-08-02	Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
IL256324B (en)	2020-06-30	Piperidine derivatives are substituted in positions 1 and 4
ZA201605622B (en)	2017-09-27	1,3-benzodioxole derivative
ZA201700019B (en)	2018-11-28	Substituted [1,2,4]triazole compounds
SI3105328T1 (sl)	2020-09-30	Multiplo genomsko inženirstvo omogočeno s CRISPR
IL247728B (en)	2019-12-31	Piperdines -(3,5 di-converted-pyridine-4-yl)-1
FR3021455B1 (fr)	2017-10-13	Procede d'aplanissement d'evidements remplis de cuivre
HRP20190107T1 (hr)	2019-03-08	Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens
PL3245198T3 (pl)	2020-10-05	Pochodne pirolidyny jako antagonisty angiotensyny ii typu 2
HRP20180585T1 (hr)	2018-07-13	Spojevi 2,7-diazaspiro[3.5]nonana
DK3237407T3 (da)	2020-07-20	3,5-diaminopyrazolkinasehæmmere
FR3021316B1 (fr)	2017-09-22	Procede d'obtention du borazane
EP3256131A4 (fr)	2019-02-27	Analogues de 3,5-dihydroxypentanoate pour la formation osseuse
FR3017730B1 (fr)	2017-05-12	Procede d'ouverture de session securise
FR3021317B1 (fr)	2016-06-17	Procede d'obtention du borazane
GB201508211D0 (en)	2015-06-24	33 1/3 / 45 / E.P. / 78 R.P.M vinyl records
ITBA20140023U1 (it)	2016-02-08	"cassetta per alimenti"
IT201700060516A1 (it)	2018-12-01	Utensile per decespugliatore
AU4985P (en)	2015-04-14	PP.1026 Cucurbita moschata
HK1253837A1 (en)	2019-07-05	Substituted 1,2-dihydro-3h
ITRA20140010U1 (it)	2015-12-19	Confezione per tartufi freschi.
UA31973S (uk)	2016-04-25	Кондитерський виріб «зайченя»
UA31972S (uk)	2016-04-25	Кондитерський виріб «жабка»